<DOC>
	<DOCNO>NCT01473875</DOCNO>
	<brief_summary>This phase 2/3 , open-label extension study evaluate long-term efficacy safety intravenous ( IV ) infusions SBC-102 child Lysosomal Acid Lipase ( LAL ) Deficiency previously receive treatment SBC-102 .</brief_summary>
	<brief_title>Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102</brief_title>
	<detailed_description>Early onset LAL Deficiency rare form LAL Deficiency , estimate prevalence le 2 life per million ( Meikle et al. , 1999 ) . This form disease , name physician first describe ( Abramov et al. , 1956 ) , aggressive presentation LAL Deficiency characterize gastrointestinal hepatic manifestation include marked growth failure , malabsorption , steatorrhea , hepatomegaly . Early onset LAL Deficiency rapidly progressive fatal usually within first year life ( Assmann &amp; Seedorf , 2001 ) . The primary objective study evaluate effect SBC-102 therapy overall survival 12 month age child growth failure due LAL Deficiency . All subject receive repeat IV infusion SBC-102 , begin least 1 week precede infusion study LAL-CL03 expand access treatment regimen .</detailed_description>
	<mesh_term>Wolman Disease</mesh_term>
	<criteria>Subject 's parent legal guardian provide write consent/permission prior study procedure Subject complete treatment study LALCL03 Subject receive treatment SBC102 least 4 month expand access treatment regimen Subject lifethreatening unmanageable study drug toxicity treatment SBC102 LALCL03 expand access treatment regimen . Clinically important concurrent disease Myeloablative preparation , systemic pretransplant conditioning , hematopoietic stem cell liver transplantation Previous hematopoietic stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>LIPA</keyword>
	<keyword>Wolman Disease</keyword>
	<keyword>Wolman Phenotype</keyword>
	<keyword>Acid Lipase Deficiency</keyword>
	<keyword>Acid Cholesteryl Hydrolase</keyword>
	<keyword>Acid Lipase Disease Deficiency , type 2</keyword>
	<keyword>Cholesteryl Ester Storage Disease ( CESD )</keyword>
	<keyword>Cholesteryl Ester Hydrolase Deficiency</keyword>
	<keyword>Early Onset LAL-Deficiency ( Wolman Disease )</keyword>
	<keyword>LAL Deficiency</keyword>
	<keyword>Late Onset Lysosomal Acid Lipase Deficiency ( CESD )</keyword>
	<keyword>Wolman Disease ( early onset LAL Deficiency )</keyword>
	<keyword>Related Disorders :</keyword>
	<keyword>Non-alcoholic Fatty Liver Disease ( NAFLD )</keyword>
	<keyword>Non-alcoholic Steatohepatitis ( NASH )</keyword>
	<keyword>Alcoholic Liver Disease</keyword>
	<keyword>Cryptogenic Cirrhosis</keyword>
	<keyword>Niemann-Pick Disease ( NPD ) Type C</keyword>
	<keyword>Chanarin Dorfman Syndrome</keyword>
</DOC>